# GPR119

## Overview
GPR119 is a gene that encodes the G protein-coupled receptor 119, a class A G protein-coupled receptor (GPCR) involved in metabolic regulation. This receptor is primarily expressed in pancreatic beta cells and intestinal enteroendocrine cells, where it plays a crucial role in glucose homeostasis by enhancing insulin release and modulating incretin hormone secretion. Structurally, GPR119 is characterized by its seven transmembrane α-helices and a unique ligand-binding pocket, which are essential for its interaction with agonists and subsequent activation of signaling pathways. The receptor's ability to influence insulin and incretin hormone secretion positions it as a potential therapeutic target for metabolic disorders such as type 2 diabetes and obesity. Despite its promising role in preclinical studies, the translation of GPR119-targeted therapies into clinical success has been challenging, with no agonists advancing beyond early-phase clinical trials (Lauffer2009GPR119; Chu2007A; Lan2009GPR119).

## Structure
The GPR119 protein is a class A G protein-coupled receptor (GPCR) characterized by a canonical architecture of seven transmembrane α-helices (TM1-TM7) connected by three extracellular loops (ECL1-ECL3) and three intracellular loops (ICL1-ICL3), along with an amphipathic helix (H8) (Qian2022Activation). The receptor exhibits unique structural features, including a distinct conformation of the second extracellular loop (ECL2), which forms an intricate structure covering the binding pocket from the extracellular side. A conserved disulfide bond between C155 in ECL2 and C78 in helix III stabilizes this loop (Qian2022Activation).

GPR119 has a noncanonical structural scaffold with a network of non-covalent contacts between residues on the TM helices, differing from other class A GPCRs. This includes five new inter-TM contacts specific to GPR119 due to a one-amino acid shift in TM5, resulting in an outward bulge and opening a hydrophobic cavity between TM4 and TM5 (Qian2022Activation). The receptor's ligand-binding pocket is highly hydrophobic and involves deep penetration of agonists, divided into three functional compartments: a stacking gate, an extracellular cavity, and an activation cavity (Qian2022Activation). These structural characteristics are crucial for receptor-ligand interactions and may impact drug discovery efforts targeting GPR119.

## Function
GPR119 is a G protein-coupled receptor primarily expressed in pancreatic beta cells and intestinal enteroendocrine cells, where it plays a significant role in glucose homeostasis. In pancreatic beta cells, GPR119 enhances glucose-dependent insulin release, which is crucial for maintaining blood glucose levels. This insulinotropic effect is mediated through a cAMP-dependent pathway, as demonstrated by the action of the GPR119 agonist AR231453, which increases cAMP accumulation and insulin secretion in response to glucose (Chu2007A).

In the intestine, GPR119 is expressed in L-cells, where it modulates the secretion of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Activation of GPR119 by agonists like oleoylethanolamide (OEA) stimulates GLP-1 release, enhancing insulin secretion and improving glucose tolerance (Lauffer2009GPR119). This receptor's role in incretin hormone release positions it as a key player in glycemic control and a potential target for therapeutic strategies aimed at treating metabolic disorders like type 2 diabetes (Chu2008A).

## Clinical Significance
GPR119 has been identified as a potential target for the treatment of type 2 diabetes due to its role in insulin and incretin hormone secretion. Alterations in GPR119 expression or function can impact glucose homeostasis and lipid metabolism, which are critical in the pathophysiology of metabolic disorders such as type 2 diabetes and obesity (Chu2007A; Lan2009GPR119). 

Mutational studies have provided insights into the receptor's activation mechanism, revealing that specific mutations can alter ligand binding and receptor activation. For instance, mutations at leucine residues L5.43(169) and L6.52(242) affect ligand interaction, with L5.43(169) being crucial for ligand binding and activation. These mutations can decrease the receptor's potency, suggesting that changes in the binding pocket shape can influence GPR119's function (Rosales2020OR2401).

Despite promising preclinical data, clinical trials for GPR119 agonists have faced challenges, with none progressing beyond Phase I. This indicates difficulties in translating preclinical findings into effective human therapies, highlighting the complexity of targeting GPR119 for diabetes treatment (Sloop2018The). The receptor's role in glucose-dependent insulinotropic actions underscores its potential as a therapeutic target, although its physiological function remains somewhat unclear (Lan2009GPR119).

## Interactions
GPR119, a G protein-coupled receptor, primarily interacts with the Gs protein to form a signaling complex. This interaction is characterized by a unique interface involving the C-terminal α5 helix of GPR119, which interacts with residues from transmembrane helices TM3, TM5, TM6, and TM7, as well as intracellular loops ICL1 and ICL2. A notable interaction occurs between E392 at the C-terminus of the α5 helix of the Gαs subunit and W282 at TM7 of GPR119, which is distinct from other class A GPCR-Gs complexes (Qian2022Activation). 

The GPR119-Gs complex is stabilized by Nb35, which bridges the Gαs and Gβγ subunits, forming a nucleotide-free complex. This stabilization is crucial for the receptor's function in cellular signaling (Qian2022Activation). The interaction with Gs involves hydrogen bonds, salt bridges, and hydrophobic interactions, with specific residues in GPR119 forming hydrogen bonds with Gαs residues (Li2024Structure). 

GPR119 also interacts with agonists such as APD597, MBX-2982, and AR231453, which bind to its ligand-binding pocket, influencing the receptor's activation and signaling pathways (Li2024Structure). These interactions are significant for drug development targeting metabolic disorders like type 2 diabetes (Li2024Structure).


## References


[1. (Li2024Structure) Ruixue Li, Yuxia Qian, Jiening Wang, Zhen Han, Sheng Ye, Shan Wu, and Anna Qiao. Structure of human gpr119-gs complex binding apd597 and characterization of gpr119 binding agonists. Frontiers in Pharmacology, January 2024. URL: http://dx.doi.org/10.3389/fphar.2024.1310231, doi:10.3389/fphar.2024.1310231. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2024.1310231)

[2. (Qian2022Activation) Yuxia Qian, Jiening Wang, Linlin Yang, Yanru Liu, Lina Wang, Wei Liu, Yun Lin, Hong Yang, Lixin Ma, Sheng Ye, Shan Wu, and Anna Qiao. Activation and signaling mechanism revealed by gpr119-gs complex structures. Nature Communications, November 2022. URL: http://dx.doi.org/10.1038/s41467-022-34696-6, doi:10.1038/s41467-022-34696-6. This article has 8 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-022-34696-6)

[3. (Chu2008A) Zhi-Liang Chu, Chris Carroll, Jean Alfonso, Veronica Gutierrez, Hongmei He, Annette Lucman, Melinda Pedraza, Helen Mondala, Hui Gao, Didier Bagnol, Ruoping Chen, Robert M. Jones, Dominic P. Behan, and James Leonard. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology, 149(5):2038–2047, January 2008. URL: http://dx.doi.org/10.1210/en.2007-0966, doi:10.1210/en.2007-0966. This article has 314 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1210/en.2007-0966)

[4. (Sloop2018The) Kyle W Sloop, Paul J Emmerson, Michael A Statnick, and Francis S Willard. The current state of <scp>gpcr</scp>‐based drug discovery to treat metabolic disease. British Journal of Pharmacology, 175(21):4060–4071, March 2018. URL: http://dx.doi.org/10.1111/bph.14157, doi:10.1111/bph.14157. This article has 40 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1111/bph.14157)

[5. (Lan2009GPR119) Hong Lan, Galya Vassileva, Aaron Corona, Li Liu, Hana Baker, Andrei Golovko, Susan J Abbondanzo, Weiwen Hu, Shijun Yang, Yun Ning, Robert A Del Vecchio, Frederique Poulet, Maureen Laverty, Eric L Gustafson, Joseph A Hedrick, and Timothy J Kowalski. Gpr119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. Journal of Endocrinology, 201(2):219–230, March 2009. URL: http://dx.doi.org/10.1677/joe-08-0453, doi:10.1677/joe-08-0453. This article has 121 citations and is from a peer-reviewed journal.](https://doi.org/10.1677/joe-08-0453)

[6. (Lauffer2009GPR119) Lina M. Lauffer, Roman Iakoubov, and Patricia L. Brubaker. Gpr119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine l-cell. Diabetes, 58(5):1058–1066, February 2009. URL: http://dx.doi.org/10.2337/db08-1237, doi:10.2337/db08-1237. This article has 290 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.2337/db08-1237)

[7. (Chu2007A) Zhi-Liang Chu, Robert M. Jones, Hongmei He, Chris Carroll, Veronica Gutierrez, Annette Lucman, Molly Moloney, Hui Gao, Helen Mondala, Didier Bagnol, David Unett, Yin Liang, Keith Demarest, Graeme Semple, Dominic P. Behan, and James Leonard. A role for β-cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology, 148(6):2601–2609, June 2007. URL: http://dx.doi.org/10.1210/en.2006-1608, doi:10.1210/en.2006-1608. This article has 250 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1210/en.2006-1608)

[8. (Rosales2020OR2401) Matthew D Rosales, Frank Dean, and Evangelia Kotsikorou. Or24-01 mutational study of the gpr119 receptor binding site. Journal of the Endocrine Society, April 2020. URL: http://dx.doi.org/10.1210/jendso/bvaa046.1659, doi:10.1210/jendso/bvaa046.1659. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1210/jendso/bvaa046.1659)